

**CENTRAL COUNCIL FOR RESEARCH IN HOMOEOPATHY
CLINICAL RESEARCH**

CONCLUDED STUDIES (upto January 2022)

Sl. no.	Sl. No.	Name of Disease*	Period of study
Mental disorders			
1.	1.	Behavioral disorders (Dis.R, GA) (Observational study)	1984 – 2005
2.	2.	Behavioral disorders (DR GA) (Observational study)	1990 – 2000
3.	3.	Depressive Episode (Observational study)	2005 – 2010
4.	4.	Schizophrenia (Observational study)	2005 – 2010
5.	5.	Treatment resistant Schizophrenia (Open label RCT)	2012-2017
Nervous system disorders			
6.	1.	Epilepsy (Dis.R, GA) (Observational study)	1980 –2003
7.	2.	Drug Validation on migraine (Observational study)	2015-2020
Ear Disorders			
8.	1.	Middle ear infection (DR, TA) (Observational study)	2003–2005
9.	2.	Acute Otitis Media (Open label pilot RCT)	2009-2010
10.	3.	Acute Otitis Media (Open label RCT)	2014-2018
Oral Disorders			
11.	1.	Periodontitis (Dis. R, GA) (Observational study)	2003-2005
Throat Disorders			
12.	1.	Tonsillitis (Dis. R GA) (Observational study)	1984 - 2003
13.	2.	Tonsillitis(DR TA) (Observational study)	1988 – 2003
Respiratory disorders			
14.	1.	Allergic Rhinitis (Dis. R, GA) (Observational study)	1989 - 1994
15.	2.	Bronchial Asthma(DR TA) (Observational study)	1988 – 2003
16.	3.	Bronchial asthma (Dis.R, GA) (Observational study)	1978 – 2003
17.	4.	Bronchial asthma (DR GA) (Observational study)	1991 – 2000
18.	5.	Bronchitis (DR TA) (Observational study)	1991- 2003
19.	6.	Bronchitis(Dis.R, GA) (Observational study)	2001- 2005
20.	7.	Chronic sinusitis (Observational study)	2005 – 2010
21.	8.	Chronic Rhinosinusitis(Double blind RCT)	2012 -2014
22.	9.	Influenza Like Illness - Open label RCT	2009 - 2010
23.	10.	PNS (Para nasal sinusitis)(DR, TA) (Observational study)	1985 - 2005
24.	11.	Respiratory Infections (DR, TA) (Observational study)	2003 – 2005

* Dis. R: Disease related, GA: General Area, DR: Drug Related, TA: tribal area, RCT: randomized controlled trial

Sl. no.	Sl. No.	Name of Disease*	Period of study
25.	12.	Rhinitis (DR, TA) (Observational study)	1989 – 2003
26.	13.	Simple and mucopurulent chronic bronchitis (Observational study)	2005 – 2010
27.	14.	Sinusitis (Dis. R, GA) (Observational study)	1984 – 2003
28.	15.	Sinusitis (DR, TA) (Observational study)	1988 – 2003
29.	16.	Tropical eosinophilia (Dis.R, GA) (Observational study)	2003 – 2005
30.	17.	Upper Respiratory Tract Infection (Dis.R, GA)	1995 – 2004
31.	18.	Drug validation acute and chronic cough (phase I study) (Observational study)	2016-2018
32.	19.	Drug Validation Chronic Cough (Observational Study)	2018-2021
33.	20.	Drug Validation on Asthma (Observational Study)	2015-2020
		Gastrointestinal Disorders	
34.	1.	Cholelithiasis (DR GA) (Observational study)	1990 - 2000
35.	2.	Cholera/Gastroenteritis (DR TA) (Observational study)	2003 – 2005
36.	3.	Dysentery (Dis.R, GA) (Observational study)	1988 – 2003
37.	4.	Dysentery (DR, TA) (Observational study)	1988 – 2003
38.	5.	Gastritis (Dis.R, GA) (Observational study)	1987 – 2005
39.	6.	Gastroenteritis (Observational study)	2005 – 2008
40.	7.	Gastroenteritis (DR ,TA) (Observational study)	1988 – 2003
41.	8.	Hemorrhoidal disease(Open label RCT)	2009 – 2010
42.	9.	Irritable bowel syndrome (Dis.R, GA) (Observational study)	1998 – 2005
43.	10.	Peptic ulcer (DR, TA) (Observational study)	1988 – 2003
44.	11.	NE GERD (Observational study)	2014-2015
45.	12.	Drug validation on Hemorrhoids(Observational study)	2015-2020
46.	13.	Drug validation on dyspepsia(Observational study)	2015-2020
		Endocrinal Disorders/ life style disorders	
47.	1.	Cephalandra indica in hyperglycemia (DR, GA) (Observational study)	1986 - 2003
48.	2.	Diabetes mellitus (Dis.R, GA) (Observational study)	1974 – 1993
49.	3.	Diabetes mellitus (DR, TA) (Observational study)	1988 – 2003
50.	4.	Diabetic Distal Symmetric (primarily sensory) Polyneuropathy (Observational study)	2005 – 2009
51.	5.	Diabetic Distal Symmetric Polyneuropathy (Double blind RCT)	2013 - 2015
52.	6.	Diabetic Foot Ulcer (Observational study)	2005 - 2009

Sl. no.	Sl. No.	Name of Disease*	Period of study
53.	7.	Diabetic neuropathy/ Diabetic foot ulcer (Dis. R, GA) (Observational study)	2003 – 2005
54.	8.	Hypertension (Dis.R, GA) (Observational study)	1990 – 2003
55.	9.	Hypertension (DR TA) (Observational study)	2003 – 2005
56.	10.	Low-density-lipoproteinemia (Dis.R, GA)	1992 – 2003
57.	11.	Hypertension (open label RCT)	2013-2018
58.	12.	Dyslipidaemia (open label RCT)	2013-2018
59.	13.	Sub clinical hypothyroidism follow up(Observational study)	2016-2018
60.	14.	Sub clinical hypothyroidism (double blind RCT)	2015-2021
61.	15.	Pre-diabetes (Open label RCT)	2013-2018
62.	16.	Diabetic foot ulcer (Open label RCT)	2014-2017
63.	17.	NCD Observational Study	2018-2020
64.	18.	Diabetes Survey (Observational study)	2021-2021
		Gynecological and obstetric disorders	
65.	1.	Cervicitis & Cervical Erosion (Dis.R, GA) (Observational study)	1981- 2004
66.	2.	Cervicitis & Cervical erosion (DR, TA) (Observational study)	1994 – 2003
67.	3.	Distressing during Climacteric Years (Observational study)	2005 – 2009
68.	4.	Malposition of human foetus (DR, GA) (Observational study)	1985 –2003
69.	5.	Menorrhagia (DR GA) (Observational study)	1985 – 2003
70.	6.	Menstrual disorders/Menopausal Syndrome (DR, TA) (Observational study)	2003 – 2005
71.	7.	Sepia in Menopause (Double blind RCT)	2012–2014
72.	8.	Uterine fibroid (Open label RCT)	2009 –2011
73.	9.	Polycystic Ovarian Syndrome (PCOS) (Open label RCT)	2014 –2015
74.	10.	Breast fibroadenoma (Open label RCT)	2014-2018
		Urological Disorders	
75.	1.	Prostatic enlargement (Dis.R, GA)	1996 – 2003
76.	2.	Renal calculi (Dis.R, GA)	1986 – 2003
77.	3.	Urolithiasis (Observational study)	2005 – 2010
78.	4.	Lycopodium in Urolithiasis (Double blind RCT)	2012 - 2015
79.	5.	Benign Prostatic Hyperplasia (Observational study)	2003-2005
80.	6.	Benign Prostatic Hyperplasia (Observational study)	2005 – 2010
81.	7.	Benign Prostatic Hyperplasia (Open label RCT)	2012 - 2015

Sl. no.	Sl. No.	Name of Disease*	Period of study
		Rheumatic disorders	
82.	1.	Arthritis (DR, TA)	1988 - 2003
83.	2.	Cervical spondylosis (DR, GA)	1998 - 2003
84.	3.	Cervical spondylosis –pain management (Open label RCT)	2009 - 2010
85.	4.	Cervical spondylosis (Double blind RCT)	2012-2013
86.	5.	Osteoarthritis (Dis.R, GA) (Observational study)	1984 - 2005
87.	6.	Osteoarthritis (DR GA) (Observational study)	1994 - 2005
88.	7.	Osteoarthritis (DR TA) (Observational study)	1988 - 2003
89.	8.	Rheumatoid arthritis (Dis.R, GA) (Observational study)	1988 - 2003
90.	9.	Traumatic arthritis (Dis.R, GA) (Observational study)	2003 - 2005
91.	10.	OA Knee (Double blind RCT)	2015-2018
92.	11.	Chronic non-specific low back pain (Open Label RCT)	2017-2019
93.	12.	Adhesive capsulitis (Observational study)	2019-2020
		Dermatology disorders	
94.	1.	Alopecia areata (Dis.R, GA) (Observational study)	1978 - 1985
95.	2.	Corns (Dis.R, GA) (Observational study)	1981 - 1985
96.	3.	Furunculosis (Observational study)	2005 - 2008
97.	4.	Leucoderma (Dis.R, GA) (Observational study)	2003 - 2005
98.	5.	Scabies(Dis.R, GA) (Observational study)	2003 - 2005
99.	6.	Skin disorders (including Allergic dermatitis, Urticaria and Psoriasis) (Dis.R, GA) (Observational study)	1980 - 2005
100.	7.	Skin disorder (Atopic dermatitis, scabies) (Observational study)	1984 - 2005
101.	8.	Vitiligo (Observational study)	2005 - 2010
102.	9.	Vitiligo (DR, GA) (Observational study)	1987 - 2005
103.	10.	Warts (Dis. R, GA)	1981 - 1985
104.	11.	Warts (observational study)	2017-2020
105.	12.	Vitiligo (Observational study)	2014-2018
106.	13.	Psoriasis (Observational study)	2015-2018
107.	14.	Paronychia(Observational study)	2019-2020
108.	15.	Calendula for Burns(Open Label RCT))	2017-2018
109.	16.	Psoriasis follow up study (Observational study)	2018-2019
110.	17.	Vitiligo follow up study(Observational study)	2018-2019
111.	18.	Drug validation on acne(Observational study)	2015-2020
		Infectious Diseases	

Sl. no.	Sl. No.	Name of Disease*	Period of study
112.	1.	Acute encephalitis syndrome (AES) (observational study)	2012- 2013
113.	2.	Amoebiasis (DR TA) (Observational study)	1988 – 2003
114.	3.	Amoebiasis (Dis. R, GA) (Observational study)	1982 – 2003
115.	4.	Amoebiasis (DR GA) (Observational study)	1987 – 2003
116.	5.	Communicable diseases (Dis. R, GA) (Observational study)	2003 – 2005
117.	6.	Fevers(DR TA) (Observational study)	2003 – 2005
118.	7.	Filaria (Dis. R, GA) (Observational study)	1979 – 2003
119.	8.	Filaria (DR, GA) (Observational study)	1982 – 2003
120.	9.	Filariasis (DR, TA) (Observational study)	1999 – 2003
121.	10.	Lymphatic Filariasis (Open label RCT)	2012 - 2014
122.	11.	Giardiasis (Dis. R, GA) (Observational study)	1998 – 2005
123.	12.	Helminthiasis (DR, GA) (Observational study)	1980 – 2003
124.	13.	Helminthiasis (DR, TA) (Observational study)	1988 – 2003
125.	14.	Hepatitis B (Dis. R, GA) (Observational study)	1998 – 2000
126.	15.	HIV infection (Observational study)	2008 - 2010
127.	16.	HIV/AIDS (Dis. R, GA) (Double blind RCT)	1995 – 1997
128.	17.	HIV/AIDS (DR GA) (Observational study)	1998 – 2004
129.	18.	HIV/AIDS (Multicentric study) (Dis. R, GA) (Observational study)	1989 – 2005
130.	19.	HIV/AIDS (pilot study) (Dis.R, GA) (Observational study)	1989 – 1991
131.	20.	Intermittent fever (Dis.R, GA) (Observational study)	1989 – 2003
132.	21.	Japanese encephalitis (DR GA) (Observational study)	1988 – 2002
133.	22.	Leptospirosis (Observational study)	2009 – 2010
134.	23.	Malaria (Dis.R, GA) (Observational study)	1979 – 2003
135.	24.	Malaria (DR, TA) (Observational study)	1987 - 2003
136.	25.	Chikungunya (Double blind RCT)	2007-2008
137.	26.	AES -treatment(Open label RCT)	2013-2015
138.	27.	AES (Preventive study), Double blind -RCT	2017-2018
139.	28.	Dengue (Comparative study) (Observational study)	2015-2015
140.	29.	AES (Retrospective -Observational study)	2016-2018
141.	30.	Asymptomatic covid19 (Open label RCT)	2020-2020
142.	31.	Covid19- Treatment study- RCT (Chirayu Hospital)	2020-2020
143.	32.	Covid19- Treatment study-RCT (Pune)	
144.	33.	Covid19 - Treatment study -RCT (AIIMS Jhajjar)	2020-2020
145.	34.	Covid19 - Treatment study -RCT (Mumbai)	2021-2021
146.	35.	Covid19-Gujarat- Observational study	2020-2020

Sl. no.	Sl. No.	Name of Disease*	Period of study
147.	36.	Impact of Covid19 on NCD (Observational study)	2020-2020
148.	37.	Covid19 prophylactic-Delhi- Observational study	2020-2020
149.	38.	Covid19 -prophylactic-RCT	2020-2020
150.	39.	Covid19-Retrospective observational study	2020-2020
151.	40.	Covid prophylactic-Delhi Police-Maharashtra (Observational study)	2020-2020
152.	41.	Covid19- Prophylactic- college- (Observational study)	2020-2020
153.	42.	Covid19 Delhi Prisons -(Observation study)	2020-2020
		Geriatric Disorders	
154.	1.	Geriatric disorders (Dis.R, GA) (Observational study)	2003- 2005
		Pediatric Disorders	
155.	1.	Acute Diarrhoeal Diseases in Children (Observational study)	2005 -2008
156.	2.	Acute Rhinitis in children (Observational study)	2005- 2008
157.	3.	Acute tracheobronchitis (Observational study)	2005 - 2008
158.	4.	Attention Deficit Hyperactivity Disorder (Pilot open label RCT)	2009 – 2011
159.	5.	Mental retardation (Dis. R, GA) (Observational study)	1991 – 2001
160.	6.	Paediatric diarrhea (Dis. R, GA) (Observational study)	1998 –2003
161.	7.	Paediatric problems (Dis. R, GA) (Observational study)	2003–2005
162.	8.	Autism- open label RCT	2012-2017
163.	9.	Adenotonsillar hypertrophy(Observational study)	2017-2020
164.	10.	Comparison of two paradigms (Hom. Vs Allopathy) (Observational study)	2018-2021
		Cancer	
165.	1.	Malignancy (Dis. R, GA) (Observational study)	1988 – 1991
166.	2.	Malignancy (DR GA) (Observational study)	1984 – 1993
167.	3.	Side effects of Chemotherapy/Radiotherapy in cancer (Observational study)	2012-2016
168.	4.	Oral mucositis due to Side effects of Chemotherapy/Radiotherapy in cancer (Observational study)	2016-2019
		Nutritional Disorders	
169.	1.	Iron deficiency anemia (Dis. R, GA) (Observational study)	1995 – 2000
170.	2.	Iron deficiency anemia (Double blind RCT)	2015-2018
		Substance abuse disorders	
171.	3.	Drug de-addiction (Dis.R, GA) (Observational study)	1988 – 1994
172.	4.	Alcohol Dependence (Open label RCT)	2012 - 2014
		Others	

Sl. no.	Sl. No.	Name of Disease*	Period of study
173.	1.	Sickle cell anemia (Dis. R, GA) (Observational study)	1987 - 2004
174.	2.	Tuberculinum (clinical proving) (Dis. R, GA) (Observational study)	1979 - 1988
175.	3.	Patient reported outcome study (Observational study)	2017-2020
176.	4.	Susceptibility-Clinical Application (Observational study)	2016-2020
177.	5.	Muriatic family (Observational study)	2017-2019
178.	6.	Vithoukas Compass-prescribing (Observational study)	2019-2020